Muhammad Furqan

3.3k total citations · 1 hit paper
114 papers, 1.8k citations indexed

About

Muhammad Furqan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Muhammad Furqan has authored 114 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 29 papers in Molecular Biology. Recurrent topics in Muhammad Furqan's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (14 papers). Muhammad Furqan is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Research Studies (14 papers). Muhammad Furqan collaborates with scholars based in United States, Pakistan and China. Muhammad Furqan's co-authors include Delong Liu, Akintunde Akinleye, Nikhil Mukhi, Yongping Song, Varun Mittal, Byung Moo Lee, Taher Abu Hejleh, Yamei Chen, Gerald H. Clamon and Zuhair K. Ballas and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Muhammad Furqan

104 papers receiving 1.8k citations

Hit Papers

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in... 2024 2026 2025 2024 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
    2024 124 citations Shubham Pant, Zev A. Wainberg et al. Nature Medicine profile →

Peers

Muhammad Furqan
Gregory D. Ayers United States
Sally Temraz Lebanon
Debra H. Josephs United Kingdom
Erin R. Gardner United States
Zeina Nahleh United States
Khalil Zaman Switzerland
Erika Cecchin Italy
Yuan Li Shen China
Lu Li China
Christian M. Kurbacher Germany
Gregory D. Ayers United States
Muhammad Furqan
Citations per year, relative to Muhammad Furqan Muhammad Furqan (= 1×) peers Gregory D. Ayers

Countries citing papers authored by Muhammad Furqan

Since Specialization
Citations

This map shows the geographic impact of Muhammad Furqan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muhammad Furqan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muhammad Furqan more than expected).

Fields of papers citing papers by Muhammad Furqan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muhammad Furqan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muhammad Furqan. The network helps show where Muhammad Furqan may publish in the future.

Co-authorship network of co-authors of Muhammad Furqan

This figure shows the co-authorship network connecting the top 25 collaborators of Muhammad Furqan. A scholar is included among the top collaborators of Muhammad Furqan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muhammad Furqan. Muhammad Furqan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653. 7 indexed citations
2.
Furqan, Muhammad, Lawrence Feldman, Greg Andrew Durm, et al.. (2025). 2761O Chemo-immunotherapy followed by durvalumab and ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer. Annals of Oncology. 36. S1369–S1370.
3.
Salem‐Bekhit, Mounir M., et al.. (2025). Photocatalytic activity of cobalt-doped Cd1-xAl0.2Fe1.8O4 (0,0.3) spinel ferrite for atrazine degradation. Reaction Kinetics Mechanisms and Catalysis. 138(3). 1653–1671. 1 indexed citations
4.
Langer, Corey J., Rachel Galot, Hans Prenen, et al.. (2024). Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.. Journal of Clinical Oncology. 42(16_suppl). 8559–8559. 1 indexed citations
5.
6.
Pant, Shubham, Zev A. Wainberg, Colin D. Weekes, et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. 30(2). 531–542. 124 indexed citations breakdown →
7.
Furqan, Muhammad, et al.. (2024). Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncology. 20(22). 1553–1563. 1 indexed citations
8.
9.
Wang, Chunli, et al.. (2024). Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study. Journal of Thoracic Disease. 16(5). 3338–3349. 1 indexed citations
10.
11.
12.
Gutierrez, Martin, Melissa Johnson, David Sommerhalder, et al.. (2022). 727 Interim phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. A760–A760. 1 indexed citations
13.
Shapiro, Geoffrey I., Amit Mahipal, Jason S. Starr, et al.. (2022). Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 7(5). 100573–100573. 34 indexed citations
14.
Hussain, Syed Makhdoom, et al.. (2021). Effectiveness of phytase pre-treatment on growth performance, nutrient digestibility and mineral status of common carp (Cyprinus carpio) juveniles fed Moringa by-product based diet. Saudi Journal of Biological Sciences. 28(3). 1944–1953. 11 indexed citations
15.
Hussain, Syed Makhdoom, et al.. (2020). Improvement in overall performance of Catla catla fingerlings fed phytase included low cost plant by products-based diet. Saudi Journal of Biological Sciences. 27(8). 2089–2096. 16 indexed citations
16.
Yadav, Meeta, Muhammad Furqan, Nathaniel C. Cady, et al.. (2019). OA03.04 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer. Journal of Thoracic Oncology. 14(11). S1132–S1132.
17.
Furqan, Muhammad, Jun Zhang, Gerald H. Clamon, & Taher Abu Hejleh. (2018). P2.12-02 Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 13(10). S791–S791. 1 indexed citations
18.
Shergill, Ardaman, Muhammad Furqan, Jyoti Malhotra, et al.. (2018). P1.01-86 BTCRC-LUN15-017: Phase-Ib Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC after Progression on Platinum Based Therapy. Journal of Thoracic Oncology. 13(10). S496–S496. 1 indexed citations
19.
Mapuskar, Kranti A., Kyle H. Flippo, Joshua D. Schoenfeld, et al.. (2017). Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. Cancer Research. 77(18). 5054–5067. 31 indexed citations
20.
Furqan, Muhammad. (2017). ANALISA PERFORMANSI GOOGLE MAPS DAN MAPBOX API PADA APLIKASI ABSEN KULIAH BERBASIS ANDROID. Electronic theses and dissertations (Syiah Kuala University). 1(1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregory D. Ayers Breakdown of academic impact, for papers by Sally Temraz Breakdown of academic impact, for papers by Debra H. Josephs Breakdown of academic impact, for papers by Erin R. Gardner Breakdown of academic impact, for papers by Zeina Nahleh Breakdown of academic impact, for papers by Khalil Zaman Breakdown of academic impact, for papers by Erika Cecchin Breakdown of academic impact, for papers by Yuan Li Shen Breakdown of academic impact, for papers by Lu Li Breakdown of academic impact, for papers by Christian M. Kurbacher
Rankless by CCL
2026